Introduction
============

Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers and causes of cancer mortality worldwide.[@B1], [@B2] Fewer than 20% of HCC patients can receive curative therapies such as surgical resection, liver transplantation and ablative therapies due to advanced disease at presentation or poor liver functional reserve.[@B3] Transarterial chemoembolization (TACE) is a widely accepted treatment for unresectable or intermediate-stage HCCs.[@B4]-[@B6] However, their prognosis remains poor.[@B6], [@B7] Extrahepatic progression following TACE is one of the important factors. However, very few studies have been reported to evaluate the risk factors for extrahepatic progression after TACE in HCC patients.

This retrospective study was designed to investigate the risk factors for extrahepatic progression after TACE in HCC patients in order to improve individualized treatment and promote precision treatment of these patients.

Materials and Methods
=====================

This research was approved by the institutional review board (IRB) of Sun Yat-sen University Cancer Center. The approval number is B2018-134-01. The experiments were carried out in accordance with the approved guidelines.

Patients
--------

Between October 2005 and September 2012, 1635 patients were newly diagnosed with HCC and received TACE as primary treatment in our department. Of these, 654 (40%) cases with complete medical records were included into the current retrospective study.

The diagnosis of HCC was based on the diagnostic criteria for HCC described in the American Association for the Study of the Liver (AASLD) guidelines.[@B5] Routine pretreatment examination included blood chemistry, serum tumor biomarker such as alpha-fetoprotein (AFP), chest radiography, ultrasonography, tri-phase contrast-enhanced helical computed tomography (CT), and/or contrast-enhanced magnetic resonance (MR) imaging of the abdomen. Further investigations were performed whenever there was clinical suspicion of extrahepatic metastases. Liver function was evaluated based on the Child-Pugh classification system [@B8] and the indocyanine green (ICG) clearance test was performed routinely within three days before treatment. The selection criteria for the TACE procedure depended on the tumor location and extent, the liver function and the general condition of the patient.

TACE procedure
--------------

TACE was performed as previously described with minor modifications.[@B6] When necessary, superselective chemoembolization was performed through the segmental or subsegmental arteries, based on the tumor location and extent and hepatic function reserve. If stasis could not be achieved in a tumor-feeding artery, iodized oil was used solely in some patients. Embolization was then performed with injection of absorbable gelfoam particles (1-2 mm in diameter) through the angiographic catheter.

Post-TACE care and follow-up
----------------------------

The posttreatment care and follow-up were performed routinely in all patients. A serum AFP assay, liver function test, and abdominal ultrasonography or tri-phase contrast-enhanced helical CT were performed monthly during the first three months. Thereafter, the patients were followed every 2-3 months with radiology and serum examination. Further investigations were performed as needed.

The modified Response Evaluation Criteria in Solid Tumors (mRECIST) was used to evaluate tumor response [@B9]. The first evaluation was performed one month after TACE. Another TACE treatment was performed every 4-8 weeks until one of the following end points was reached: (1) complete devascularization of the tumor, (2) technical impossibility to embolize the residual tumors, (3) development of contraindications to embolization, and (4) total resection or ablation of the tumor by subsequent surgery or local ablation. The proper subsequent treatment was defined as the clinical routine. The follow-up ended on January 31, 2018.

Statistical analysis
--------------------

Comparisons between categorical variables were performed using Pearson\'s χ2 test or Fisher\'s exact test where appropriate. Continuous variables were compared using Student\'s t-test (when values were normally distributed) or the Mann-Whitney test (when values had a distribution that departed significantly from normal). The survival analysis was calculated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate analyses using Cox\' proportional hazard model were performed to evaluate the prognostic factors. The correlation between two variables was examined by Pearson\'s correlation analysis (when values were normally distributed) or Spearman\'s correlation analysis (when values had a distribution that departed significantly from normal). A value of p\<0.05 was considered statistically significant. All data were analyzed using SPSS statistical software for Windows (ver. 18.0; SPSS Inc., Chicago, IL, USA).

All continuous variable data are expressed as the mean ± standard error (when values were normally distributed) or the median (range) (when values had a distribution that departed significantly from normal). All data regarding categorical variables are shown as n (proportion).

Results
=======

Baseline clinical characteristics
---------------------------------

The baseline clinical characteristics of 654 HCC patients treated with TACE are summarized in Table [1](#T1){ref-type="table"}. In the study cohort, the mean age was 51.23 years; most of the patients were male (603 cases, 92.20%) and hepatitis B surface antigen positive (576 cases, 88.07%). Serum AFP level was higher than 400 ng/ml in approximately half of the patients (332 cases, 50.76%). The liver function was good in most of the patients classified as Child-Pugh A (564 cases, 86.24%) and B (85 cases, 13.00%); the median ICG 15 minute retention (ICGR15) was 6.1%. There were 249 cases (38.07%) staged as stage A, 160 cases (24.46%) as stage B, 243 cases (37.16%) as stage C, and 2 cases (0.31%) as stage D, according to the BCLC algorithm. Seventy cases (10.70%) had extrahepatic metastases, and 207 cases (31.65%) had portal/hepatic vein tumor thrombosis.

Tumor response and subsequent treatment
---------------------------------------

The tumor response to initial TACE was evaluated in 645 patients, as shown in Table [1](#T1){ref-type="table"}. The CR rate, response rate (RR), and disease control rate (DCR) were 9.92%, 25.89%, and 70.39%, respectively.

The subsequent treatment was chosen based on the tumor location and extent, the liver function and the general condition of the patient as shown in Table [2](#T2){ref-type="table"}. Overall, 172 cases (26.30%) received 342 cycles of radical treatments afterwards.

Survival and progression
------------------------

At a median follow-up time of 12.7 months (range, 0.1-127), 532 patients (81.35%) had died. Of these, 4 patients died without any radiographic progression, which were counted in extrahepatic progression as shown in Table [3](#T3){ref-type="table"}. The median overall survival (OS) period was 14.5 (95% confidence interval (CI), 12.6-16.3) months. The overall survival is shown in Fig. [1](#F1){ref-type="fig"}. The 6-month, 1-, 2-, 3-, and 5-year OS rates were 75.5%, 55.0%, 33.9%, 22.8%, and 14.9%, respectively. During the follow-up period, 488 patients (74.62%) had disease progression. The median progression-free survival (PFS) period was 4.3 (95% CI, 3.6-5.0) months. The progression-free survival is shown in Fig. [2](#F2){ref-type="fig"}. The 6-month, 1-, 2-, 3-, and 5-year PFS rates were 40.7%, 27.1%, 16.7%, 13.9%, and 9.3%, respectively. Overall, 150 patients developed extrahepatic progression as shown in Table [3](#T3){ref-type="table"}.

Prognostic factors for overall survival
---------------------------------------

Univariate and multivariate analysis of factors affecting OS are shown in Table [4](#T4){ref-type="table"}. Age ≤50 yr, having not received radical treatment after initial TACE, a maximum tumor diameter≥10 cm, the presence of extrahepatic metastasis before initial TACE, the presence of portal/hepatic vein tumor thrombosis before initial TACE, AFP \>400 ng/ml, platelet count (PLT)\>100×109/L, alanine aminotransferase (ALT) \>40 U/L, aspartate transaminase (AST)\>45 U/L, albumin (ALB) \<35 g/L, total bilirubin (TBil) \>20.5 μmol/L, Child-Pugh score \>6, B/C/D stage according to the BCLC staging system, lipiodol dose during TACE \>15 ml, the use of gelfoam during TACE, and tumor response that were evaluated as PD and SD after initial TACE and found to be statistically significant by univariate analysis were included in a multivariate regression analysis. The results of the latter demonstrated that not having received radical treatment after initial TACE (p\<0.001, HR: 2.868; 95% CI: 2.292-3.589), a maximum tumor diameter ≥10 cm (p=0.016, HR: 1.327; 95% CI: 1.054-1.669), the presence of portal/hepatic vein tumor thrombosis (p=0.004, HR: 1.427; 95% CI: 1.120-1.817), AFP \>400 ng/ml (p=0.001, HR: 1.353; 95% CI: 1.125-1.629), AST \>45 U/L (p=0.001, HR: 1.534; 95% CI: 1.200-1.960), and a tumor response that had been evaluated as PD and SD after initial TACE (p\<0.001, HR: 1.829; 95% CI: 1.480-2.261) were independent predictors of poorer prognosis of OS.

Prognostic factors for progression-free survival
------------------------------------------------

Similarly, univariate and multivariate analyses of factors affecting PFS are shown in Table [5](#T5){ref-type="table"}. Not having received radical treatment after initial TACE, a maximum tumor diameter ≥10 cm, the presence of extrahepatic metastasis before initial TACE, the presence of portal/hepatic vein tumor thrombosis before initial TACE, AFP \>400 ng/ml, white blood cell count (WBC) \>4.0×109/L, PLT \>100×109/L, AST \>45 U/L, ALB \<35 g/L, Child-Pugh score \>6, stage B/C/D according to the BCLC staging system, lipiodol dose during TACE \>15 ml, and tumor response that were evaluated as PD and SD after initial TACE and found to be statistically significant by univariate analysis were included in a multivariate regression analysis. The results of the latter revealed that not having received radical treatment after initial TACE (p\<0.001, HR: 1.663; 95% CI: 1.347-2.053), portal/hepatic vein tumor thrombosis (p=0.021, HR: 1.339; 95% CI: 1.044-1.717), AST \>45 U/L (p=0.024, HR: 1.279; 95% CI: 1.032-1.586), and tumor response that were evaluated as PD and SD after initial TACE (p\<0.001, HR: 2.032; 95% CI: 1.629-2.534) were independent predictors of poorer prognosis of PFS.

Prognostic factors for extrahepatic progression-free survival
-------------------------------------------------------------

Additionally, univariate and multivariate analyses of factors affecting extrahepatic PFS are shown in Table [6](#T6){ref-type="table"}. Age ≤50 yr, not having received radical treatment after initial TACE, maximum tumor diameter ≥10 cm, the presence of extrahepatic metastasis before initial TACE, the presence of portal/hepatic vein tumor thrombosis before initial TACE, AFP \>400 ng/ml, PLT \>100×109/L, AST \>45 U/L, ALB \<35 g/L, stage B/C/D according to the BCLC staging system, lipiodol dose during TACE \>15 ml, and tumor response that were evaluated as PD and SD after initial TACE and found to be statistically significant by univariate analysis were included in a multivariate regression analysis. The results of the latter revealed that not having received radical treatment after initial TACE (p\<0.001, HR: 2.629; 95% CI: 1.697-4.072), the presence of extrahepatic metastasis before initial TACE (p\<0.001, HR: 2.259; 95% CI: 1.432-3.563), AST \>45 U/L (p=0.024, HR: 1.612; 95% CI: 1.065-2.439), ALB \<35 g/L (p=0.012, HR: 1.803; 95% CI: 1.135-2.862), and tumor response that were evaluated as PD and SD after initial TACE (p\<0.001, HR: 2.608; 95% CI: 1.670-4.071) were independent predictors of poorer prognosis of extrahepatic PFS.

Discussion
==========

Although TACE has been widely used as a palliative therapy worldwide, especially in China and other Asian countries [@B6], [@B10]-[@B12], single TACE treatment is not recommended whenever extrahepatic metastasis is present [@B5], [@B13]. The BCLC staging classification recommends the administration of sorafenib as the first line treatment for HCC patients who have extrahepatic metastasis [@B5], [@B14]. A previous study showed that the prognosis of HCC patients with extrahepatic metastasis is significantly worse than that of advanced HCC patients without extrahepatic metastasis [@B15]. These results suggest that advanced HCC patients with extrahepatic metastasis or extrahepatic progression after TACE need combination treatments with TACE and systematic therapy, including sorafenib or radiotherapy [@B4], which makes identifying the risk factors for extrahepatic progression after TACE a matter of considerable importance.

In the present study, several factors were found to be associated with OS and PFS. Some factors are well accepted in previous reports, such as tumor size, portal vein invasion, and AFP level [@B16]-[@B18]. Of note, while the tumor size, portal vein invasion, and AFP level were associated with OS and PFS, these factors were not significant predictors of extrahepatic progression in the present study, suggesting that in advanced HCC, the tumor burden in the liver itself is unrelated to extrahepatic progression after TACE treatment. It is controversial from the clinical point of view and numerous previous studies. In univariate analysis these factors are of significance. However, these may be obscured by other factors in the multivariate analysis. Although AFP can show good prognostic ability in most of the time, it is not an absolutely accurate prognostic indicator for extrahepatic progression. Tumor thrombi are meaningful in both multivariate analysis of OS and PFS, but show no significance in extrahepatic PFS. It may indicate that tumor thrombus is more likely to cause intrahepatic dissemination, rather than the progress of extrahepatic lesions in TACE treatment.

In the present study, the presence of extrahepatic metastasis did not affect OS and PFS, which is inconsistent with a previous study [@B15]. However, the presence of extrahepatic metastasis before TACE is an independent risk factor for extrahepatic progression. The results may be ascribed to the patients with extrahepatic metastasis suitable to accept combination treatment strategy such as systematic treatment and/or radiotherapy, which could enhance the anti-tumor effect compared to TACE alone.

Similarly, hypoproteinemia (albumin lower than 35 g/L) is a unique risk factor for extrahepatic progression, while other biomarkers for liver function such as total bilirubin, prothrombin time, ICGR15, alanine aminotransferase, and aspartate aminotransferase did not demonstrate prognostic prediction power for extrahepatic progression. This observation may suggest that albumin level plays quite a unique role in HCC patients, especially advanced patients. The treatment options of a significant number of patients may be limited by hypoproteinemia, making repeat TACE, combination therapy or other treatments impossible.

An increased AFP level has been associated with larger tumors and lower hypohepatia, reflecting an aggressive biology [@B19]. In present study, AFP \>400 ng/ml is associated with OS, which is consistent with a previous report [@B20]. However, no association was found with PFS and extrahepatic PFS, suggesting that TACE may inhibit the aggressive behavior of high AFP level tumors; this hypothesis needs further verification.

Of note, in the present study, extrahepatic metastasis present before TACE is an independent risk factors for extrahepatic progression after TACE, which is consistent with previous report [@B21]. Leal, et al. mentioned the patterns of progression were different between patients with and without extrahepatic metastasis. Based on the results of present and previous studies, we suggest apply combination therapy including target therapy and/or radiotherapy as early as possible in patients with extrahepatic metastasis.

We acknowledge some weaknesses in our study. First, the nature of retrospective study brought choose bias inevitably, the results needs further prospective study to confirm. Second, the chemotherapy regimen in TACE were various, which made the analysis more complex while making the results closer to real clinical practice at the same time in fact. Finally, to obtain the generalizability of our results, another validation cohort from other centers rather than our single center might be necessary.

In conclusion, we identified that the presence of extrahepatic metastasis before TACE, AST \>45 U/L, ALB \<35 g/L, and lack of response after TACE as independent risk factors for extrahepatic progression. To gain better therapeutic outcome and survival, early combination treatment including target therapy and/or radiotherapy was strongly recommended in these patients.
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###### 

Baseline clinical characteristics and evaluation of tumor response after initial TACE in 654 HCC patients

  Baseline clinical characteristics        n=654; mean±SE, median (range), or n (proportion)
  ---------------------------------------- ---------------------------------------------------
  Age (years)                              51.23±0.48
  Gender                                   
  Male                                     603 (92.20%)
  Female                                   51 (7.80%)
  HBsAg status                             
  Negative                                 65 (9.94%)
  Positive                                 576 (88.07%)
  Unknown                                  13 (1.99%)
  Preoperative AFP level                   
  ≤400 ng/ml                               322 (49.24%)
  \>400 ng/ml                              332 (50.76%)
  Preoperative ALT level (U/L)             45.4 (6\~667.4)
  Preoperative AST level (U/L)             57 (13\~521)
  Preoperative TBil level (umol/L)         15.4 (2.92\~128)
  Preoperative ALB level (g/L)             40.15±0.18
  Preoperative WBC level (10^9^/L)         6.6 (2\~27)
  Preoperative PLT level (10^9^/L)         176 (16\~594)
  Preoperative PT level (s)                12.6 (8.7\~22.8)
  Preoperative Child-Pugh score            
  A5                                       333 (50.92%)
  A6                                       231 (35.32%)
  B7                                       63 (9.63%)
  B8                                       18 (2.75%)
  B9                                       4 (0.61%)
  C10                                      2 (0.31%)
  Unknown                                  3 (0.46%)
  Preoperative ICGR15 (%)                  6.1 (0\~57.4)
  Number of tumors                         
  Solitary                                 399 (61.01%)
  Multiple                                 255 (38.99%)
  Maximum diameter of tumor (cm)           8.8 (1\~22)
  Extrahepatic metastasis                  
  Negative                                 584 (89.30%)
  Positive                                 70 (10.70%)
  Portal/Hepatic vein tumor thrombosis     
  Negative                                 447 (68.35%)
  Positive                                 207 (31.65%)
  BCLC stage                               
  Stage A                                  249 (38.07%)
  Stage B                                  160 (24.46%)
  Stage C                                  243 (37.16%)
  Stage D                                  2 (0.31%)
  Lipiodol dose (ml)                       15 (0\~70)
  Use of gelfoam                           
  No                                       543 (83.03%)
  Yes                                      111 (16.97%)
  Tumor response to initial TACE (n=645)   
  CR                                       64 (9.92%)
  PR                                       103 (15.97%)
  SD                                       287 (44.50%)
  PD                                       191 (29.61%)
  Postoperative hospital stay (days)       5 (1\~105)

TACE: transcatheter arterial chemoembolization; HBsAg: hepatitis B surface antigen; AFP: alpha fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: albumin; WBC: white blood cell; PLT: blood platelet; PT: prothrombin time; BCLC: Barcelona Clinic Liver Cancer; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease

###### 

The subsequent treatment following initial TACE of all patients

  Treatment                            Cases   Cycles
  ------------------------------------ ------- --------
  Radical treatment                            
  Resection for primary lesion         46      49
  RFA for primary lesion               85      121
  PMCT for primary lesion              64      115
  PEI for primary lesion               31      46
  Cryoablation for primary lesion      6       8
  Transplantation                      3       3
  Palliative treatment                         
  TACE                                 323     555
  TAI                                  9       10
  Systemic chemotherapy                19      55
  Sorafenib                            45      \-
  Radiotherapy                         18      19
  Sealed source radiotherapy           7       13
  Resection for metastatic lesion      1       1
  PMCT for metastatic lesion           4       5
  RFA for metastatic lesion            3       6
  Cryoablation for metastatic lesion   1       1
  CIK cell therapy                     5       12

RFA: radiofrequency ablation; PMCT: percutaneous microwave tumor coagulation therapy; PEI: percutaneous ethanol injection therapy; TACE: transcatheter arterial chemoembolization; TAI: transarterial infusion chemotherapy; CIK: cytokine-induced killer

###### 

The characteristics of 150 patients with extrahepatic progression

  Site of extrahepatic progression   Cases
  ---------------------------------- -------
  Lung                               83
  Lymph node(s)                      24
  Bone                               13
  Lung+lymph node(s)                 8
  Adrenal gland(s)                   7
  Death                              4
  Bone+lymph node(s)                 2
  Lung+bone                          1
  Lung+adrenal gland+lymph nodes     1
  Peritoneum                         1
  Chest wall                         1
  Lung+adrenal gland+chest wall      1
  Peritoneum+bone+muscle             1
  Lung+peritoneum+pleura             1
  Peritoneum+lymph nodes             1
  Adrenal gland+lymph nodes          1

###### 

Univariate and multivariate analyses of factors affecting OS

                                                 Univariate Cox regression analysis for OS   Multivariate Cox regression analysis for OS                                 
  ---------------------------------------------- ------------------------------------------- --------------------------------------------- ------- ------- ------------- -------
  Male                                           1.076                                       0.77-1.503                                    0.668                         
  Age (≤50 yr)                                   1.261                                       1.063-1.496                                   0.008   1.071   0.888-1.293   0.472
  No radical treatment                           3.146                                       2.54-3.895                                    0.000   2.868   2.292-3.589   0.000
  Single lesion                                  1.045                                       0.877-1.245                                   0.623                         
  Maximum tumor diameter (≥10 cm)                2.080                                       1.743-2.483                                   0.000   1.327   1.054-1.669   0.016
  Extrahepatic metastasis present                1.361                                       1.046-1.772                                   0.022   0.945   0.707-1.263   0.702
  Portal/hepatic vein tumor thrombosis present   2.323                                       1.933-2.791                                   0.000   1.427   1.120-1.817   0.004
  AFP (\>400 ng/ml)                              1.677                                       1.412-1.992                                   0.000   1.353   1.125-1.629   0.001
  WBC (\>4.0×10^9^/L)                            1.202                                       0.891-1.623                                   0.228           \-            
  PLT (\>100×10^9^/L)                            1.281                                       1.022-1.607                                   0.032   1.090   0.841-1.413   0.513
  ALT (\>40 U/L)                                 1.315                                       1.104-1.567                                   0.002   0.956   0.77-1.186    0.682
  AST (\>45 U/L)                                 1.981                                       1.645-2.387                                   0.000   1.534   1.200-1.960   0.001
  ALB (\<35 g/L)                                 1.338                                       1.043-1.717                                   0.022   1.203   0.886-1.633   0.237
  TBil (\>20.5 μmol/L)                           1.236                                       1.018-1.502                                   0.033   1.022   0.813-1.284   0.853
  HBsAg positive                                 1.154                                       0.868-1.534                                   0.323           \-            
  PT (\>13.5 s)                                  1.142                                       0.942-1.384                                   0.176           \-            
  ICGR15 (\>10%)                                 1.166                                       0.952-1.428                                   0.138           \-            
  Child-Pugh score (\>6)                         1.394                                       1.08-1.799                                    0.011   1.240   0.88-1.747    0.219
  BCLC stage (B/C/D)                             1.436                                       1.202-1.717                                   0.000   1.163   0.927-1.459   0.191
  Lipiodol dose (\>15 ml)                        1.684                                       1.416-2.001                                   0.000   0.953   0.772-1.177   0.653
  Use of gelfoam                                 1.268                                       1.017-1.581                                   0.035   1.054   0.822-1.351   0.680
  PD+SD after initial TACE                       2.058                                       1.674-2.53                                    0.000   1.829   1.480-2.261   0.000

OS: overall survival; AFP: alpha fetoprotein; WBC: white blood cell; PLT: blood platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: albumin; HBsAg: hepatitis B surface antigen; PT: prothrombin time; ICG: indocyanine green; BCLC: Barcelona Clinic Liver Cancer; SD: stable disease

###### 

Univariate and multivariate analyses of factors affecting PFS

                                                 Univariate Cox regression analysis for PFS                 Multivariate Cox regression analysis for PFS                            
  ---------------------------------------------- -------------------------------------------- ------------- ---------------------------------------------- -- ------- ------------- -------
  Male                                           1.279                                        0.902-1.814   0.152                                                                   
  Age (≤50 yr)                                   1.151                                        0.963-1.375   0.122                                                                   
  No radical treatment                           1.883                                        1.538-2.305   0.000                                             1.663   1.347-2.053   0.000
  Multiple lesions                               1.015                                        0.847-1.217   0.870                                                                   
  Maximum tumor diameter (≥10 cm)                1.507                                        1.25-1.818    0.000                                             1.022   0.813-1.284   0.855
  Extrahepatic metastasis present                1.501                                        1.125-2.004   0.006                                             1.275   0.934-1.741   0.126
  Portal/hepatic vein tumor thrombosis present   1.872                                        1.543-2.27    0.000                                             1.339   1.044-1.717   0.021
  AFP (\>400 ng/ml)                              1.280                                        1.07-1.53     0.007                                             1.081   0.893-1.308   0.425
  WBC (\>4.0×10^9^/L)                            1.543                                        1.107-2.149   0.010                                             1.044   0.718-1.52    0.821
  PLT (\>100×10^9^/L)                            1.335                                        1.052-1.693   0.017                                             1.217   0.917-1.615   0.174
  ALT (\>40 U/L)                                 1.146                                        0.956-1.375   0.141                                                                   
  AST (\>45 U/L)                                 1.503                                        1.244-1.815   0.000                                             1.279   1.032-1.586   0.024
  ALB (\<35 g/L)                                 1.440                                        1.105-1.875   0.007                                             1.260   0.918-1.73    0.152
  TBil (\>20.5 umol/L)                           1.019                                        0.828-1.254   0.861                                                                   
  HBsAg negative                                 1.007                                        0.753-1.347   0.964                                                                   
  PT (\>13.5 s)                                  1.071                                        0.877-1.308   0.501                                                                   
  ICGR15 (\>10%)                                 1.206                                        0.978-1.487   0.080                                                                   
  Child-Pugh score (\>6)                         1.330                                        1.015-1.741   0.038                                             1.292   0.924-1.806   0.134
  BCLC stage (B/C/D)                             1.370                                        1.139-1.647   0.001                                             1.115   0.888-1.401   0.347
  Lipiodol dose (\>15 ml)                        1.341                                        1.118-1.607   0.002                                             0.987   0.795-1.226   0.907
  Use of gelfoam                                 1.150                                        0.914-1.445   0.233                                                                   
  PD+SD after initial TACE                       2.202                                        1.78-2.725    0.000                                             2.032   1.629-2.534   0.000

PFS: progression-free survival; AFP: alpha fetoprotein; WBC: white blood cell; PLT: blood platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: albumin; HBsAg: hepatitis B surface antigen; PT: prothrombin time; ICG: indocyanine green; BCLC: Barcelona Clinic Liver Cancer; SD: stable disease

###### 

Univariate and multivariate analyses of factors affecting extrahepatic PFS

                                                 Univariate Cox regression analysis for extrahepatic progression-free survival                 Multivariate Cox regression analysis for extrahepatic progression-free survival                            
  ---------------------------------------------- ------------------------------------------------------------------------------- ------------- --------------------------------------------------------------------------------- -- ------- ------------- -------
  Male                                           1.184                                                                           0.64-2.189    0.591                                                                                                      
  Age (≤50 yr)                                   1.723                                                                           1.245-2.385   0.001                                                                                1.387   0.965-1.994   0.077
  No radical treatment                           3.093                                                                           2.027-4.72    0.000                                                                                2.629   1.697-4.072   0.000
  Single lesion                                  1.388                                                                           0.985-1.957   0.061                                                                                                      
  Maximum tumor diameter (≥10 cm)                2.419                                                                           1.743-3.358   0.000                                                                                1.143   0.76-1.719    0.520
  Extrahepatic metastasis present                2.916                                                                           1.939-4.385   0.000                                                                                2.259   1.432-3.563   0.000
  Portal/hepatic vein tumor thrombosis present   2.577                                                                           1.85-3.589    0.000                                                                                1.460   0.943-2.261   0.090
  AFP (\>400 ng/ml)                              1.770                                                                           1.276-2.454   0.001                                                                                1.206   0.842-1.729   0.307
  WBC (\>4.0×10^9^/L)                            1.477                                                                           0.819-2.667   0.195                                                                                                      
  PLT (\>100×10^9^/L)                            1.808                                                                           1.117-2.927   0.016                                                                                1.292   0.755-2.211   0.350
  ALT (\>40 U/L)                                 1.323                                                                           0.947-1.85    0.101                                                                                                      
  AST (\>45 U/L)                                 2.141                                                                           1.48-3.096    0.000                                                                                1.612   1.065-2.439   0.024
  ALB (\<35 g/L)                                 1.839                                                                           1.194-2.832   0.006                                                                                1.803   1.135-2.862   0.012
  TBil (≤20.5 umol/L)                            1.033                                                                           0.707-1.51    0.865                                                                                                      
  HBsAg negative                                 1.044                                                                           0.62-1.757    0.871                                                                                                      
  PT (≤13.5 s)                                   1.096                                                                           0.753-1.595   0.632                                                                                                      
  ICGR15 (\>10%)                                 1.076                                                                           0.738-1.570   0.703                                                                                                      
  Child-Pugh score (\>6)                         1.546                                                                           0.981-2.436   0.060                                                                                                      
  BCLC stage (B/C/D)                             1.544                                                                           1.099-2.168   0.012                                                                                0.969   0.613-1.533   0.894
  Lipiodol dose (\>15 ml)                        1.848                                                                           1.338-2.554   0.000                                                                                1.105   0.752-1.624   0.611
  Use of gelfoam                                 1.150                                                                           0.763-1.735   0.504                                                                                                      
  PD+SD after 1st TACE                           2.984                                                                           1.945-4.576   0.000                                                                                2.608   1.670-4.071   0.000

AFP: alpha fetoprotein; WBC: white blood cell; PLT: blood platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: albumin; HBsAg: hepatitis B surface antigen; PT: prothrombin time; ICG: indocyanine green; BCLC: Barcelona Clinic Liver Cancer; SD: stable disease
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